T cell-based immunotherapy for recurrent bladder cancer

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-14005726

Enrollment

Unknown

Registered

2014-12-30

Start date

2013-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

treatment group:radiotherapy, chemotherapy, immunotherapy

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: recurrent bladder cancer was diagnosed based on imaging studies and pathology; no chance to operat. No acute and serious complications, including bleeding,organ failure, older than 18 years.

Exclusion criteria

Exclusion criteria: Autoimmune diseases; severe allergic or adverse reactions; syphilis, AIDS, failure of important organs, uncontrolled diabetes.

Design outcomes

Primary

Measure	Time frame
tumor;tumor marker;Flow Cytometry;T cell receptor;recurrence;	—

Countries

China

Contacts

Public ContactMingxin Dong

839409586@qq.com+86 13804412605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026